×
0 0 0 0 0 0 0 0
Stockreport

Advanced Accelerator in-licenses PET imaging agent for prostate cancer [Seeking Alpha]

ADVANCED ACCELERATOR APPLICATIONS SA AMERICAN DE (AAAP)  More Company Research Source: Seeking Alpha
Last advanced accelerator applications sa american de earnings: 8/31 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: adacap.com/investor-relations
PDF Advanced Accelerator in-licenses PET imaging agent for prostate cancerNovartis (NVS+0.8%) unit Advanced Accelerator Applications S.A. inks anexclusive global license with privately held Cancer Targeted Technology securing development and commercialization rights to CTT1057, a ligand of prostate-specific membrane antigen (PSMA) for positron-emission tomography (PET) imaging of prostate cancer.Under the terms of the deal, Advanced Accelerator will pay an upfront fee, milestones and royalties on net sales. Specific financial terms are not disclosed.Click to subscribe to real-time analytics on NVSNow read:Teva Or Amgen/Novartis, Who Will Win The Battle For Migraine Market Share? » [Read more]

IMPACT SNAPSHOT EVENT TIME: AAAP
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
AAAP alerts
from News Quantified